Showing 2471-2480 of 7280 results for "".
Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE Fails
https://practicaldermatology.com/topics/clinical-case-reports/chitotriosidase-providing-confirmation-of-sarcoidosis-when-ace-fails/26642/Chitotriosidase: Providing Confirmation of Sarcoidosis When ACE FailsDermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Pulse's CellFX, Soliton's RAP Technology, Belotero Balance (+), Restylane Defyne, Eczema Costs
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pulses-cellfx-solitons-rap-technology-belotero-balance-restylane-defyne-eczema-costs/19899/The FDA has cleared Pulse Biosciences’ CellFX system, and a commercial rollout will begin soon. There’s another new option for treatment for legs with FDA clearance of Soliton’s Rapid Acoustic Pulse technology for cellulite. For eight percent of Americans with atopic dermatitis, annual out of pocketAltreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobL'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-l-oreal-nabs-cerave-smart-beauty-tools-skin-cancer-knowledge-lacking/18703/Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell itsQuantel Derma LEDA Diode Laser System - Hair Removal at the Speed of Light
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/quantel-derma-leda-diode-laser-system-hair-removal-at-the-speed-of-light/19447/LEDA is the expandable platform system for permanent hair removal at the speed of light. LEDA applies photodynamic therapy (PDT) for the treatment of acne, Psoriasis, Vitiligo & atopic dermatitis, and for gentle skin rejuvenation. The diode laser system LEDA EPI, for hair removal, has a large spDermwireTV: FDA Approves Humira Biosimilar; Study Examines Trifarotene for Acne Lesions
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approves-humira-biosimilar-study-examines-trifarotene-acne-lesions/24513/In this episode of DermwireTV, the FDA approves a high-concentration Humira biosimilar; a study finds trifarotene combined with a skincare regimen was effective for acne-induced hyperpigmentation; the FDA accepts Dermavant's NDA for Vtama cream for AD; and the PA Perspective series addresses buildinDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesUnleashing Revenue Growth:Harnessing Patient Data
https://practicaldermatology.com/topics/practice-management/unleashing-revenue-growth-harnessing-patient-data/26968/Unleashing Revenue Growth: Harnessing Patient DataInside LEVEL UP: Lead Investigator Discusses Upadacitinib Study
https://practicaldermatology.com/topics/atopic-dermatitis/inside-level-lead-investigator-discusses-upadacitinib-study/26661/Inside LEVEL UP: Lead Investigator Discusses Upadacitinib Study